Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Buy
55
UCBJY Quote, Financials, Valuation and Earnings
Last price:
$97.35
Seasonality move
:
5.08%
Day range:
$95.24 - $97.48
52-week range:
$42.50 - $99.51
Dividend yield:
0.75%
P/E ratio:
148.21x
P/S ratio:
6.48x
P/B ratio:
3.85x
Volume:
8.8K
Avg. volume:
9.6K
1-year change:
133.01%
Market cap:
$36.9B
Revenue:
$5.7B
EPS (TTM):
$0.66
Analysts' Opinion
-
Consensus RatingUCB SA has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, UCB SA has an estimated downside of -- from its current price of $97.35.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $97.35.
Fair Value
-
According to the consensus of 0 analysts, UCB SA has -- downside to fair value with a price target of -- per share.
UCBJY vs. S&P 500
-
Over the past 5 trading days, UCB SA has overperformed the S&P 500 by 4.87% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
UCB SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
UCB SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter UCB SA reported revenues of --.
Earnings Growth
-
UCB SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter UCB SA reported earnings per share of --.
Enterprise value:
39.3B
EV / Invested capital:
--
Price / LTM sales:
6.48x
EV / EBIT:
85.17x
EV / Revenue:
6.68x
PEG ratio (5yr expected):
--
EV / Free cash flow:
64.06x
Price / Operating cash flow:
62.07x
Enterprise value / EBITDA:
32.49x
Gross Profit (TTM):
$4B
Return On Assets:
1.53%
Net Income Margin (TTM):
4.4%
Return On Equity:
2.64%
Return On Invested Capital:
2.01%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.5B | $3.5B | $3.4B | $3.3B | $3.6B | |
| Total Assets | $14.9B | $15.5B | $17B | $16.7B | $16.8B | |
| Current Liabilities | $2.9B | $2.8B | $3B | $2.9B | $3B | |
| Total Liabilities | $6.9B | $6.4B | $7.7B | $6.9B | $7.2B | |
| Total Equity | $8B | $9.1B | $9.3B | $9.8B | $9.6B | |
| Total Debt | $3.1B | $2.3B | $3B | $3B | $3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
UCBJY
Sector
Market Cap
$36.9B
$44.6M
Price % of 52-Week High
97.83%
45.71%
Dividend Yield
0.75%
0%
Shareholder Yield
1.49%
-0.68%
1-Year Price Total Return
133.01%
-29.09%
Beta (5-Year)
0.733
0.772
Dividend yield:
0.75%
Annualized payout:
$0.73
Payout ratio:
107.92%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$96.10
200-day SMA
Buy
Level
$80.27
Bollinger Bands (100)
Buy
Level
87.32 - 96.58
Chaikin Money Flow
Buy
Level
1.4M
20-day SMA
Buy
Level
$96.61
Relative Strength Index (RSI14)
Buy
Level
54.90
ADX Line
Buy
Level
8.29
Williams %R
Neutral
Level
-40.6863
50-day SMA
Buy
Level
$95.39
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
1.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4777)
Buy
CA Score
(Annual)
Level (0.1736)
Buy
Beneish M-Score
(Annual)
Level (-2.5042)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-1.2338)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Stock Forecast FAQ
In the current month, UCBJY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UCBJY average analyst price target in the past 3 months is --.
-
Where Will UCB SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that UCB SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About UCB SA?
Analysts are divided on their view about UCB SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UCB SA is a Sell and believe this share price will rise from its current level to --.
-
What Is UCB SA's Price Target?
The price target for UCB SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UCBJY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for UCB SA is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of UCBJY?
You can purchase shares of UCB SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UCB SA shares.
-
What Is The UCB SA Share Price Today?
UCB SA was last trading at $97.35 per share. This represents the most recent stock quote for UCB SA. Yesterday, UCB SA closed at $97.35 per share.
-
How To Buy UCB SA Stock Online?
In order to purchase UCB SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
